A liver-targeting fluorescent nano-drug for theranostics in non-alcoholic fatty liver disease

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Hepatology

Background:

• Non-alcoholic fatty liver disease (NAFLD) is a chronic condition marked by liver fat accumulation, often linked to obesity or drug injury.
• Early theranostic intervention is critical for non-obese, drug-induced NAFLD patients to prevent liver cancer progression.
• Current treatments lack integrated diagnostic and therapeutic capabilities for real-time monitoring.

Purpose of the Study:

• To develop an intrinsically fluorescent nanodrug (LIGHT) for simultaneous diagnosis and treatment of NAFLD.
• To create a drug with hepatic fat-targeting and lipid droplet-guiding capabilities.
• To enable real-time monitoring of therapeutic efficacy in NAFLD patients.

Main Methods:

• Development of LIGHT (lipid droplet-guiding and hepatotropic targeting) nanodrug.
• In vitro testing using free fatty acids (FFAs)-induced steatosis hepatocyte model.
• In vivo testing in a NAFLD mice model following intravenous administration.

Main Results:

• LIGHT demonstrated high affinity for intracellular lipid droplets and rapid hepatotropic accumulation.
• The nanodrug effectively reduced lipid deposition in the steatosis hepatocyte model.
• LIGHT enabled real-time monitoring of liver lesions and restored normal liver morphology and function in NAFLD mice.

Conclusions:

• The developed nanodrug LIGHT offers an integrated theranostic solution for NAFLD.
• LIGHT simplifies theranostic operations through its "target-image-therapy" strategy.
• This approach significantly improves the efficacy of NAFLD treatment and monitoring.